<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lu SZ</submitter><funding>Ministry of Science and Technology of China</funding><funding>Key Realm R&amp;amp;D Program of Guangdong Province</funding><funding>Strategic Priority Research Program of Chinese Academy of Science</funding><funding>Innovative Research Team of High-Level Local Universities in Shanghai</funding><funding>National Natural Science Foundation of China</funding><funding>NINDS NIH HHS</funding><funding>Shanghai Municipal Science and Technology</funding><pagination>e20210998</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9350686</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>219(9)</volume><pubmed_abstract>Astrocyte activation is associated with progressive inflammatory demyelination in multiple sclerosis (MS). The molecular mechanisms underlying astrocyte activation remain incompletely understood. Recent studies have suggested that classical neurotransmitter receptors are implicated in the modulation of brain innate immunity. We investigated the role of dopamine signaling in the process of astrocyte activation. Here, we show the upregulation of dopamine D2 receptor (DRD2) in reactive astrocytes in MS brain and noncanonical role of astrocytic DRD2 in MS pathogenesis. Mice deficient in astrocytic Drd2 exhibit a remarkable suppression of reactive astrocytes and amelioration of experimental autoimmune encephalomyelitis (EAE). Mechanistically, DRD2 regulates the expression of 6-pyruvoyl-tetrahyd</pubmed_abstract><journal>The Journal of experimental medicine</journal><pubmed_title>Inhibition of astrocytic DRD2 suppresses CNS inflammation in an animal model of multiple sclerosis.</pubmed_title><pmcid>PMC9350686</pmcid><funding_grant_id>P30 NS057098</funding_grant_id><funding_grant_id>U1801681</funding_grant_id><funding_grant_id>R01 NS039055</funding_grant_id><funding_grant_id>2018SHZDZX05</funding_grant_id><funding_grant_id>2018B030337001</funding_grant_id><funding_grant_id>2020YFC2002800</funding_grant_id><funding_grant_id>XDB32020100</funding_grant_id><pubmed_authors>Xiao YC</pubmed_authors><pubmed_authors>Guo YS</pubmed_authors><pubmed_authors>Yin YQ</pubmed_authors><pubmed_authors>Liang XM</pubmed_authors><pubmed_authors>Zhou JW</pubmed_authors><pubmed_authors>Liang PZ</pubmed_authors><pubmed_authors>Yin S</pubmed_authors><pubmed_authors>Liu YF</pubmed_authors><pubmed_authors>Lu SZ</pubmed_authors><pubmed_authors>Zhang XL</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Wang HY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inhibition of astrocytic DRD2 suppresses CNS inflammation in an animal model of multiple sclerosis.</name><description>Astrocyte activation is associated with progressive inflammatory demyelination in multiple sclerosis (MS). The molecular mechanisms underlying astrocyte activation remain incompletely understood. Recent studies have suggested that classical neurotransmitter receptors are implicated in the modulation of brain innate immunity. We investigated the role of dopamine signaling in the process of astrocyte activation. Here, we show the upregulation of dopamine D2 receptor (DRD2) in reactive astrocytes in MS brain and noncanonical role of astrocytic DRD2 in MS pathogenesis. Mice deficient in astrocytic Drd2 exhibit a remarkable suppression of reactive astrocytes and amelioration of experimental autoimmune encephalomyelitis (EAE). Mechanistically, DRD2 regulates the expression of 6-pyruvoyl-tetrahyd</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-05T12:56:45.53Z</modification><creation>2025-04-05T12:56:45.53Z</creation></dates><accession>S-EPMC9350686</accession><cross_references><pubmed>35877595</pubmed><doi>10.1084/jem.20210998</doi></cross_references></HashMap>